Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Astrazeneca (AZNCF) Gross Profit (2016 - 2025)

Historic Gross Profit for Astrazeneca (AZNCF) over the last 16 years, with Q4 2025 value amounting to $12.4 billion.

  • Astrazeneca's Gross Profit rose 180.01% to $12.4 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $48.1 billion, marking a year-over-year increase of 966.58%. This contributed to the annual value of $48.1 billion for FY2025, which is 966.58% up from last year.
  • According to the latest figures from Q4 2025, Astrazeneca's Gross Profit is $12.4 billion, which was up 180.01% from $12.4 billion recorded in Q3 2025.
  • Over the past 5 years, Astrazeneca's Gross Profit peaked at $12.4 billion during Q3 2025, and registered a low of $5.5 billion during Q1 2021.
  • For the 5-year period, Astrazeneca's Gross Profit averaged around $9.3 billion, with its median value being $9.4 billion (2023).
  • In the last 5 years, Astrazeneca's Gross Profit surged by 6362.01% in 2021 and then skyrocketed by 180.01% in 2025.
  • Quarter analysis of 5 years shows Astrazeneca's Gross Profit stood at $7.4 billion in 2021, then grew by 12.47% to $8.3 billion in 2022, then grew by 16.96% to $9.7 billion in 2023, then rose by 25.22% to $12.2 billion in 2024, then increased by 1.8% to $12.4 billion in 2025.
  • Its Gross Profit stands at $12.4 billion for Q4 2025, versus $12.4 billion for Q3 2025 and $12.0 billion for Q2 2025.